Table 1.
Oncolytic CVB3 virotherapy for cancer treatment.
| Target Cells for CVB3 | Cancer Model; Route of Application | CVB3 Variant | MiR-Regulation | Aimed de-Targeting of | Reference | |
|---|---|---|---|---|---|---|
| human breast cancer cells (TNBC cells) | mouse MDA-MB-468 xenograft; intratumoral | not stated | tissue‑specific | miR-1 miR-217 |
pancreas, heart | [108] |
| human colorectal carcinoma cells | mouse DLD-1 xenograft; intratumoral | PD | miR-375 miR-1 |
pancreas, heart | [107] | |
| human colorectal cancer cells | colorectal cancer cells | attenuated H3 | miR-375 | pancreatic cells | [109] | |
| human lung cancer cells (KRASmut lung adenocarcinoma non‑SCLC, TP53mut/RB1mut SCLC cells) | mouse H526-derived TP53mut/RB1mut SCLC xenograft; intraperitoneal |
Nancy | tumor suppressor | miR-145 miR-143 |
heart, lung (lung epithelial cells, cardiomyocytes) | [105] |
| lung cancer cells (non‑SCLC H1299, TC-1) | mouse H1299 xenograft and TC‑1 syngeneic lung cancer model; intratumoral | Nancy | miR-34a miR-34c |
normal cells | [103] | |
| human lung cancer cells (non‑SCLC) | mouse GLC-82, A549, H460 xenograft; intravenous | attenuated Nancy—modified with basic peptide | - | - | - | [110] |
| human lung cancer cells (KRASmut lung adenocarcinoma non‑SCLC) | mouse H2030 xenograft; intratumoral | Nancy | - | - | - | [104] |
| various cancer cell lines, esp. human non‑SCLC lung cancer cells | mouse A549, H1299, EBC-1 xenograft and TC‑1 syngeneic lung cancer model; intratumoral | Nancy | - | - | - | [20] |
| human EC cells | mouse HEC-1-A, HEC-1-B, Ishikawa xenograft; intratumoral, intravenous | CV-B3/2035A | - | - | - | [91] |
| human colorectal cancer cells | mouse DLD-1 xenograft; intratumoral | PD, Nancy, H3 and 31-1-93 | - | - | - | [92] |
TNBC, triple-negative breast cancer; KRAS, Kirsten rat sarcoma viral oncogene; SCLC, small-cell lung cancer; RB, retinoblastoma protein; TP, tumor protein; EC, endometrial cancer.